Recent Updates
Recently added Catalysts
ELTX Positive Sentiment Score: 75/100

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Monday, February 5, 2024 1 min read
Key Takeaway: Elicio Therapeutics announced that its CEO, Robert Connelly, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be accessible via a live webcast, allowing investors to follow Elicio's developments in immunotherapy. Elicio focuses on innovative treatments targeting lymph nodes to enhance immune response against aggressive cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Elicio Therapeutics is developing novel immunotherapies for cancer treatment.
  • The presentation at a significant healthcare conference highlights Elicio's progress and visibility.
  • The webcast providing on-demand access increases engagement with investors and stakeholders.

Full Press Release Details

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.
A live webcast of the presentation will be accessible under “Events” in the Investors section of Elicio’s website and will be available on-demand for 90 days following the event.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.
LifeSci Communications
kpoliti@lifescicomms.com
Investor Relations Contact

Frequently Asked Questions

What type of company is Elicio Therapeutics?

Elicio Therapeutics is a clinical-stage biotechnology company focused on cancer immunotherapies.

When will Elicio's CEO present at the Oppenheimer conference?

Robert Connelly will present on February 13, 2024, at 12:40 PM ET.

How can I watch Elicio's presentation?

The presentation will be live-streamed on Elicio's website and available on-demand for 90 days.

What are Elicio's novel therapies targeting?

Elicio is developing therapies that target lymph nodes to enhance immune responses against cancer.

What types of products is Elicio developing?

Elicio is engineering AMPlifiers, immunomodulators, adjuvants, and vaccines for aggressive cancers.

Tags: ELTX Viatris Investor Conferences Healthcare Elicio Therapeutics cancer immunotherapy Oppenheimer Conference healthcare
Last updated: Feb 5, 2024